In our previously-published clinical trial we used HER-2 peptide-pulsed, IL-12-secreting dendritic cells as vehicles for vaccinating against an early form of HER-2pos breast cancer [8, 9, 10]. The gene discussed is ERBB2; the disease is breast carcinoma.